Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality.
Although the antiplatelet agent clopidogrel is associated with an increased incidence of thrombotic thrombocytopenic purpura (TTP), available evidence is not sufficient to establish or disprove a causal relationship. We review and assess the evidence and case reports linking clopidogrel use with TTP and discuss how to approach the risk of TTP in patients taking clopidogrel.
Majhail
Navneet S
NS
Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Lichtin
Alan E
AE
D015984:Causality; D000077144:Clopidogrel; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D018570:Risk Assessment; D013988:Ticlopidine / Q000009:adverse effects* / Q000031:analogs & derivatives
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine